FDA OKs Pfizer's abuse deterrent opioid Troxyca ER

Aug. 20, 2016 3:12 PM ETPfizer Inc. (PFE)By: Douglas W. House, SA News Editor19 Comments
  • The FDA approves Pfizer's (NYSE:PFE) abuse-deterrent TROXYCA ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for the management of pain severe enough to require around-the-clock long-term opioid treatment and for which alternative treatment options are inadequate.
  • The product is formulated in pellets with a core of sequestered naltrexone hydrochloride, an opioid antagonist, surrounded by the pain medication oxycodone hydrochloride. When taken as directed, the naltrexone remains sequestered while the patient receives extended-release oxycodone. When the pellets are crushed, naltrexone is released which counteracts the effects of the opioid.

Recommended For You

Comments (19)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.